These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37691435)

  • 1. Effect of Hydroxyurea Therapy on Growth Parameters in Older Children (6-15 Year-Old) with Sickle Cell Disease: Low Dose Versus High Dose.
    Khater D; Al-Mulaabed S; Alomairi A; Elshinawy M; Soliman A; Elshinawy N; Wali Y; Al Yaarubi S
    Hemoglobin; 2023 Nov; 47(4):157-162. PubMed ID: 37691435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
    Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
    Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea and growth in young children with sickle cell disease.
    Rana S; Houston PE; Wang WC; Iyer RV; Goldsmith J; Casella JF; Reed CK; Rogers ZR; Waclawiw MA; Thompson B;
    Pediatrics; 2014 Sep; 134(3):465-72. PubMed ID: 25157002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of Seminal Fluid Parameters and Fertility of Male Sickle Cell Disease Patients and Potential Impact of Hydroxyurea Treatment.
    Sahoo LK; Kullu BK; Patel S; Patel NK; Rout P; Purohit P; Meher S
    J Assoc Physicians India; 2017 Jun; 65(6):22-25. PubMed ID: 28782309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.
    Jones KM; Niaz MS; Brooks CM; Roberson SI; Aguinaga MP; Hills ER; Rice VM; Bourne P; Bruce D; Archibong AE
    Int J Environ Res Public Health; 2009 Mar; 6(3):1124-44. PubMed ID: 19440437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea for the treatment of sickle cell disease.
    Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
    Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
    Lagunju I; Brown BJ; Oyinlade AO; Asinobi A; Ibeh J; Esione A; Sodeinde OO
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27252. PubMed ID: 29797633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.
    Heitzer AM; Longoria J; Okhomina V; Wang WC; Raches D; Potter B; Jacola LM; Porter J; Schreiber JE; King AA; Kang G; Hankins JS
    Br J Haematol; 2021 Oct; 195(2):256-266. PubMed ID: 34272726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
    Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
    Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of avascular necrosis of the femoral head in children with sickle cell disease on hydroxyurea: MRI evaluation.
    Adekile AD; Gupta R; Al-Khayat A; Mohammed A; Atyani S; Thomas D
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27503. PubMed ID: 30345708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease.
    Joseph L; Jean C; Manceau S; Chalas C; Arnaud C; Kamdem A; Pondarré C; Habibi A; Bernaudin F; Allali S; de Montalembert M; Boutonnat-Faucher B; Arlet JB; Koehl B; Cavazzana M; Ribeil JA; Lionnet F; Berthaut I; Brousse V
    Blood; 2021 Feb; 137(6):826-829. PubMed ID: 32976551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study.
    de Montalembert M; Voskaridou E; Oevermann L; Cannas G; Habibi A; Loko G; Joseph L; Colombatti R; Bartolucci P; Brousse V; Galactéros F;
    Am J Hematol; 2021 Oct; 96(10):1223-1231. PubMed ID: 34224583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
    Voskaridou E; Christoulas D; Bilalis A; Plata E; Varvagiannis K; Stamatopoulos G; Sinopoulou K; Balassopoulou A; Loukopoulos D; Terpos E
    Blood; 2010 Mar; 115(12):2354-63. PubMed ID: 19903897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.
    de Montalembert M; Belloy M; Bernaudin F; Gouraud F; Capdeville R; Mardini R; Philippe N; Jais JP; Bardakdjian J; Ducrocq R; Maier-Redelsperger M; Elion J; Labie D; Girot R
    J Pediatr Hematol Oncol; 1997; 19(4):313-8. PubMed ID: 9256830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
    Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
    Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.